Transgene

Stocks

Market Closed - Euronext Paris 23:55:00 03/09/2026 HKT			5-day change	1st Jan Change
0.8850 ^EUR	+12.45%		+9.12%	-7.81%

09-03	Transgene jumps 20% on positive cancer vaccine data in early trial	RE
09-03	Transgene: no cases of recurrence at three years among patients treated with TG4050

Published on 06/29/2026 at 10:35 pm HKT - Modified on 06/30/2026 at 04:52 am HKT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the Transgene virtual key opinion leader event. At this time, all attendees are in a listen-only mode and a

[

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

09-03	Transgene jumps 20% on positive cancer vaccine data in early trial	RE
09-03	Transgene: no cases of recurrence at three years among patients treated with TG4050
09-03	Transgene And NEC Corporation Report 100% Three-Year Disease-Free Survival With TG4050 And Publish Phase 1 Results In Nature Communications	CI
06-29	Transgene SA - Special Call
06-25	Oddo BHF Stays Positive on Transgene
06-25	Positive Preclinical Data for a Transgene Vaccine
06-25	Transgene Presents Preclinical Data Demonstrating Robust Protection Against Mpox With Its Novel Scalable Cell Line?Derived MVA Vaccine Candidate TG-MVATM	CI
06-22	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine	CI
06-22	Transgene launches a clinical trial evaluating TG4070 with nivolumab
06-22	Transgene Begins Phase 1 Trial of Non-small Cell Lung Cancer Vaccine	MT
05-22	Transgene SA Announces Board Appointments	CI
04-13	Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer	CI
04-07	Transgene stands out following licensing agreement with NEC Bio
04-03	Transgene, NEC Bio Enter Partnership to Develop Cancer Vaccine	MT
04-03	Transgene and NEC Bio Sign License Agreement for TG4050 Development in Head and Neck Cancer	CI

Duration

Period

Sector